ClinicalTrials.gg
Not yet recruitingNCT07289178Updated Dec 17, 2025

Effect of Liposome Bupivacaine Serratus Plane Block on Postoperative Hyperalgesia and Chronic Post-surgical Pain in Patients Undergoing Radical Mastectomy

A Phase 1/2 interventional study of Serratus Plane block (single injection) in Serratus Plane Block, Postoperative Hyperalgesia and Chronic Post-surgical Pain, sponsored by First Affiliated Hospital of Kunming Medical University. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by First Affiliated Hospital of Kunming Medical University · Phase 1/2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 249 studies in Pain, Postoperative with a site in China — 79 open to participants now, 81 under way, 3 of them phase 3. Pain, Postoperative · China.

Planned enrollment
111th of 206
120 · median 131
Started
2026
with 35 others
Phase 1/2
2 of 249
1 open now
Primary completion
2026-10
later than 43 of 80 live
Registered
203rd of 249
by date

Among the 249 studies in Pain, Postoperative with a site in China, this one is the 111th largest by planned enrollment of the 206 interventional ones that give a count, is one of 36 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 43 of the 80 other live ones, and was the 203rd registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

79 of the 249 studies in Pain, Postoperative with a site in China are open now. Recruiting first, the newest first:

74 more — sign in →

All 79 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Pain, Postoperative with a site in China, or all of them as a file.
02

Study summary

Radical mastectomy is currently the mainstream surgical treatment for breast cancer. Patients often experience significant postoperative pain, and some may develop chronic pain. General anesthesia is commonly used, with remifentanil being the most frequently used intraoperative analgesic. However, prolonged high-dose use of remifentanil can induce opioid-induced hyperalgesia (OIH). Previous studies have shown that serratus anterior plane block can reduce acute postoperative pain after radical mastectomy, but it remains unclear whether it can reduce postoperative pain sensitization and the incidence of chronic pain. Liposomal bupivacaine is a new long-acting local anesthetic with an effect lasting up to 72 hours. This study aims to investigate the effect of liposomal bupivacaine serratus anterior plane block on postoperative pain sensitization and chronic pain in patients undergoing radical mastectomy, providing a reference for clinical treatment. The study includes 120 participants. A tactile measurement kit is used to measure the mechanical pain threshold around the surgical incision preoperatively and at 24 and 48 hours postoperatively, as well as postoperative persistent pain scores at 7 days, 1 month, 3 months, and 6 months. The data will then be analyzed to draw conclusions.

Read the detailed description

This study is a prospective, randomized, double-blind trial. Approved by the hospital ethics committee, patients signed informed consent forms. A total of 120 patients scheduled for elective radical mastectomy under general anesthesia were selected, with ASA classifications I-IV, aged 18-80 years, and BMI \<30 kg/m². They were randomly divided into four groups using a computer-generated randomization method: low-dose remifentanil with saline pre-pectoral nerve block group (LR NS), high-dose remifentanil with saline pre-pectoral nerve block group (HR NS), high-dose remifentanil with ropivacaine pre-pectoral nerve block group (HR L), and high-dose remifentanil with liposomal bupivacaine pre-pectoral nerve block group (HR B). Patient general information, anesthesia time, surgery time, remifentanil dosage, and the doses of saline, ropivacaine, and liposomal bupivacaine for the pre-pectoral nerve block were recorded. Non-invasive blood pressure (MAP) and heart rate (HR) were measured before anesthesia induction, before intubation, immediately after intubation, at skin incision, during skin closure, and at extubation. Intraoperative vasoactive drugs usage and doses were also recorded. Postoperative NRS pain scores were assessed at 1h, 6h, 24h, and 48h, along with the amount of rescue analgesics used within 24h after surgery, the number of patients requiring rescue analgesia, and any adverse reactions such as postoperative nausea, vomiting, dizziness, drowsiness, and respiratory depression. Preoperatively and at 24h and 48h postoperatively, patients' mechanical pain thresholds around the surgical incision area and forearm were measured using a tactile measurement kit (Von Frey filaments). Postoperative recovery quality scores were recorded on day 1 and day 3, and persistent postoperative pain assessment scores were recorded at 7 days, 1 month, 3 months, and 6 months after surgery.

The research solutions, including remifentanil (40 μg/mL), 0.665% bupivacaine liposome (20 mL), and 0.375% ropivacaine (20 mL), were prepared by specialized anesthesiologists. The placebo group was prepared with only normal saline, and the preparation process was kept confidential from the investigators. Anesthesia was administered by two designated anesthesiologists according to the established trial protocol. No premedication was given to any patient. Upon entering the operating room, heart rate (HR), standard electrocardiogram (ECG), oxygen saturation (SpO2), and non-invasive blood pressure (MAP) were monitored every 5 minutes. The mean of three consecutive HR and MAP values was taken as the baseline. Bispectral index (BIS) and neuromuscular monitoring with 4-train-of-four (TOF) stimuli were also conducted. In the low-dose remifentanil group (LR), remifentanil was infused at 0.1 μg/(kg·min); in the high-dose remifentanil group (HR), remifentanil was continuously infused at 0.3 μg/(kg·min). During induction of anesthesia, remifentanil infusion continued until the completion of skin closure. General anesthesia was induced with propofol 2.0 mg/kg and rocuronium 0.9 mg/kg. When BIS \< 60 and TOF count was 0, an enhanced endotracheal tube was inserted orally using either a direct laryngoscope or a video laryngoscope, using a size 7.0 tube for female patients. Mechanical ventilation was controlled, with fresh gas flow of oxygen-air mixture (50% O2) at 2 L/min, tidal volume 6-8 mL/kg, and respiratory rate of 10-12 breaths/min, maintaining end-tidal CO2 at 35-40 mmHg. Anesthesia was maintained with sevoflurane to keep BIS between 40-60. Rocuronium 0.2 mg/kg was administered intermittently if the TOF count reached 0.4. When mean arterial pressure \< 60 mmHg, 6 mg of ephedrine was given intravenously. If heart rate \< 50 bpm, 0.5 mg of atropine was given intravenously. At the end of skin closure, sevoflurane and remifentanil infusion were stopped, and 50 mg of flurbiprofen ester was administered intravenously for analgesia. Once the TOF ratio recovered to greater than 90%, 2 mg/kg of sugammadex sodium was given to reverse residual neuromuscular blockade. The endotracheal tube was removed when the patient had sufficient spontaneous tidal volume and was awake enough to respond correctly to verbal commands, and the patient was transferred to the PACU. When the Steward score reached 6, the patient was transferred to the ward.

After anesthesia induction, the same experienced anesthesiologist performed an ultrasound-guided serratus anterior plane block on the surgical side. The skin was routinely disinfected and draped. A linear 10-13 MHz ultrasound probe was used to locate the 5th rib along the mid-axillary line to identify the superficial latissimus dorsi and the deep serratus anterior muscles. A 22G (80 mm) nerve block needle was inserted in-plane from anterolateral to posteroinferior. When the needle tip reached the surface of the serratus anterior muscle, with clear visualization of the tip in place, no aspiration of fluid, and no air, a test dose of 2 ml was first administered. After a hypoechoic area was observed on the ultrasound, and no blood or air was aspirated again, 20 ml of 0.375% ropivacaine was slowly injected in the ropivacaine group, 20 ml of 0.665% liposomal bupivacaine in the liposomal bupivacaine group, and 20 ml of saline in the placebo group, with real-time ultrasound visualization of the spread of the local anesthetic (or saline). Throughout the procedure, the patient's vital signs were monitored. In case of local anesthetic toxicity, basic life support was immediately initiated, 20% lipid emulsion was rapidly administered intravenously, and preparations were made for prolonged monitoring and advanced life support.

Tactile measurement kits (Von Frey filaments) were used to assess the mechanical pain sensitivity thresholds of patients around the surgical incision and on the forearm at preoperative (T1), 24 hours postoperative (T2), and 48 hours postoperative (T3) time points. The method for measuring mechanical pain thresholds around the incision involved testing at points 2 cm from both ends of the surgical incision and 2 cm below the center of the incision, and the average of the three measurements was taken. For the forearm, measurements were taken at points 3, 6, and 9 cm from the midpoint of the elbow, and again, the average of the three points was calculated. The tactile measurement kit consists of filaments of varying thickness, with filament weight corresponding to different levels of mechanical stimulation intensity. The specific measurement procedure was as follows: the patient closed their eyes, and the investigator applied the filaments vertically to the patient's skin until the filament bent, holding for 1.5 seconds; filaments ranging from 15 to 180 g were used, starting with the 15 g filament and progressing in ascending order; if the patient showed no response or reported sensation as touch, the filament strength was increased; if the patient reported a tingling sensation, the filament strength was decreased. The up-down method was used to calculate the mechanical pain threshold. The up-down method is a classical approach to measure mechanical pain thresholds and estimates the 50% mechanical pain threshold, calculated using the formula 50% threshold (g) = Xf + kd, where Xf represents the weight corresponding to the last filament stimulus, k is the maximum likelihood estimation value, and d is the log value of the difference between consecutive stimulus intensities. A smaller calculated value indicates a lower pain threshold.

Patients were assessed for persistent pain at 7 days, 1 month, 3 months, and 6 months postoperatively. The evaluation questions included: (1) Whether chronic pain exists;(2) Type of pain: stabbing pain, electric shock-like pain, swelling pain, numbness of the skin, etc.;(3) Pain location: breast area, ipsilateral axilla, ipsilateral upper arm, other areas (such as lower back pain and headache). Pain intensity was assessed using the NRS from 0 to 10. Pain levels were calculated separately at rest (for example, pain intensity when sitting or lying down) and during movement (for example, pain intensity when moving the ipsilateral upper arm or walking);(4) Whether pain changed after adjuvant therapy: post-operative adjuvant therapy includes radiotherapy, chemotherapy, endocrine therapy, or HER2-targeted therapy;(5) Whether pain was treated: taking analgesics, acupuncture, electrotherapy, and nerve blocks;(6) Whether the patient had previous surgeries and whether they also had long-term pain symptoms.

Statistical analyses were performed using SPSS 17.0 software. The Shapiro-Wilk test was used to assess the normality of data in each group. Normally distributed measurement data were expressed as mean ± standard deviation and analyzed using one-way or repeated measures ANOVA, with Bonferroni test for pairwise comparisons. Non-normally distributed measurement data were expressed as median (M) and interquartile range (IQR) and analyzed using the non-parametric Kruskal-Wallis test, with Mann-Whitney U test for pairwise comparisons. Categorical data were compared using the χ2 test or Fisher's exact test. P \< 0.05 was considered statistically significant.

03

Conditions studied

  • Serratus Plane Block
  • Postoperative Hyperalgesia
  • Chronic Post-surgical Pain
  • Liposomal Bupivacaine
  • Radical Mastectomy Surgery

Browse trials for

Keywords

  • serratus plane block
  • postoperative hyperalgesia
  • chronic post-surgical pain
  • Liposomal Bupivacaine
  • Radical mastectomy surgery
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Select patients scheduled for elective radical mastectomy for breast cancer under general anesthesia, I-IV, aged 18-80 years.

Exclusion criteria

Exclusion Criteria:

Allergy to the anesthetics used, infection at the puncture site, history of chronic pain and current use of opioid analgesics, history of chest surgery or trauma, drug or alcohol dependence, neurological or psychiatric disorders, severe hepatic or renal insufficiency, pregnancy, (BMI) greater than 30 kg/m².

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Placebo comparator
    Low-dose remifentanil saline serratus plane block group

    Anesthesia induction began with continuous infusion of remifentanil until skin suturing was completed at a low dose of 0.1 μg/(kg·min). After anesthesia induction, 20 ml of normal saline was used for the preoperative quadratus lumborum block group.

    Procedure: Serratus Plane block (single injection)

  • Placebo comparator
    Hight-dose remifentanil saline serratus plane block group

    Anesthesia induction began with continuous infusion of remifentanil until skin suturing was completed at a high dose of remifentanil 0.3 μg/(kg·min). After anesthesia induction, 20 ml of normal saline was used for the preoperative serratus anterior muscle block group.

    Procedure: Serratus Plane block (single injection)

  • Active comparator
    Highight-dose remifentanil with 0.375% ropivacaine serratus plane block group

    Anesthesia induction began with continuous infusion of remifentanil until the completion of skin suturing, with a high-dose remifentanil infusion rate of 0.3 μg/(kg·min). After anesthesia induction, a pre-saw muscle block was performed using 20 ml of 0.375% ropivacaine.

    Procedure: Serratus Plane block (single injection)

  • Experimental
    Highight-dose remifentanil with 0.665% Liposomal Bupivacaine serratus plane block group

    Anesthesia induction began with a continuous infusion of remifentanil until the end of skin suturing, at a high dose of remifentanil infusion at 0.3 μg/(kg·min). After anesthesia induction, 20 ml of 0.665% liposomal bupivacaine was administered for a serratus plane block

    Procedure: Serratus Plane block (single injection)

Interventions

  • ProcedureSerratus Plane block (single injection)

    After anesthesia induction, the same experienced anesthesiologist performed an ultrasound-guided serratus anterior plane block on the surgical side. The skin was routinely disinfected and draped. A linear 10-13 MHz ultrasound probe was used to locate the 5th rib along the mid-axillary line to identify the superficial latissimus dorsi and the deep serratus anterior muscles. A 22G (80 mm) nerve block needle was inserted in-plane from anterolateral to posteroinferior. When the needle tip reached the surface of the serratus anterior muscle, with clear visualization of the tip in place, no aspiration of fluid, and no air, a test dose of 2 ml was first administered. After a hypoechoic area was observed on the ultrasound, and no blood or air was aspirated again, 20 ml of 0.375% ropivacaine was slowly injected in the ropivacaine group, 20 ml of 0.665% liposomal bupivacaine in the liposomal bupivacaine group, and 20 ml of saline in the placebo group, with real-time ultrasound visualization of t

06

What researchers measure

Primary outcomes

  1. Mechanical pain threshold around the postoperative incision

    Tactile measurement kits (Von Frey filaments) were used to assess patients' mechanical pain detection thresholds around the surgical incision area and the forearm preoperatively (T1), 24 hours postoperatively (T2), and 48 hours postoperatively (T3). The method for measuring mechanical pain thresholds involved measuring the threshold around the incision at two points 2 cm from either end of the incision and one point 2 cm below the middle of the incision, with the average of the three points taken as the final value. For the forearm, measurements were taken at points 3, 6, and 9 cm from the midpoint of the elbow, and the average of these three points was calculated similarly. The tactile measurement kit consists of filaments of varying thicknesses, with the filament weight corresponding to different levels of mechanical stimulus intensity.

    Time frame: Detected preoperatively (T1), 24 hours postoperatively (T2), and 48 hours postoperatively (T3)

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Oct 2026, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Dec 17, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
Oct 1, 2026
CompletionEst.
Dec 30, 2026
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07289178
Lead sponsor
First Affiliated Hospital of Kunming Medical University
Responsible party
Haixia Jiang (Clinical Professor of The first affiliated hospital of KUNMING medical university, First Affiliated Hospital of Kunming Medical University) — Principal investigator
First posted
Dec 17, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Oct 1, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Dec 17, 2025

Study contacts

Haixia Jiang
Contact
18875200060@163.com
+86-18875200060

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion